Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease - 07/02/19
, Mohamed O. Abdel-Malek a, Heba A. Osman b, Essam M. Abdel-Aziz c, Abdel-Kader A. Hashim d, Helal F. Hetta e, Khairy H. Morsy fBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
| pagine | 6 |
| Iconografia | 1 |
| Video | 0 |
| Altro | 0 |
Abstract |
Background |
Till now, pooled data about the safety and efficacy of different direct-acting antiviral (DAAs) regimens in different renal situations are still under evaluation.
Aim |
To evaluate a real-life experience of the efficacy and safety of ombitasvir/paritaprevir/ritonavir plus ribavirin (OBV/PTV/r plus RIB) in patients with end-stage kidney disease (ESKD).
Patients and methods |
Between January 2017 and January 2018, an open-label multicenter prospective study was designed to enroll all consecutive patients with proven CHC genotype 4 infections and concomitant ESKD based on estimated glomerular filtration rate (eGFR) with (HD group) or without hemodialysis (non-HD group). Patients were given a co-formula of OBV/PTV/r (25/150/100 mg) once-daily plus RIB was given for 12 weeks. Sustained virologic response (SVR 12) was the primary endpoint.
Results |
A total of 110 patients were enrolled. An overall SVR 12 was reported in 104 (94.5%) patients, and treatment failure were reported in 6 patients [2 patients (1.8%) were relapsed, and 4 patients (3.6%) patients were non-responders]. SVR12 was 96% in HD and 91.4% in non-HD patients (P = 0.286).
There were no reported serious adverse events. Anemia was reported in 66.6% (n = 50) in HD group and in 31.4% (n = 11) in non-HD group.
Conclusion |
Although it is still challenging, achievement of SVR12 in patients with chronic HCV and concomitant end-stage kidney disease in the era of DAAs became possible with a 12 weeks course of a co-formula of ombitasvir/paritaprevir /ritonavir plus ribavirin.
ClinicalTrials.gov ID |
NCT03341988.
Il testo completo di questo articolo è disponibile in PDF.Abbreviation : HD
Keywords : HCV, End-stage kidney disease, DAAs
Mappa
Vol 43 - N° 1
P. 82-87 - Febbraio 2019 Ritorno al numero
Articolo precedente
- Assessment of liver fibrosis by transient elastography (Fibroscan®) in patients with A1AT deficiency
- Olivier Guillaud, Jérôme Dumortier, Julie Traclet, Lioara Restier, Philippe Joly, Colette Chapuis-Cellier, Alain Lachaux, Jean François Mornex
- Life expectancy in pancreatic neuroendocrine cancer
- Jordan C. Brooks, Robert M. Shavelle, Kate N. Vavra-Musser
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?